Literature DB >> 30119869

Humanistic burden of chronic pruritus in patients with inflammatory dermatoses: Results of the European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) cross-sectional trial.

Sabine Steinke1, Claudia Zeidler2, Claudia Riepe2, Philipp Bruland3, Iñaki Soto-Rey3, Michael Storck3, Matthias Augustin4, Svetlana Bobko5, Simone Garcovich6, Franz J Legat7, Andrey Lvov5, Laurent Misery8, Nani Osada3, Adam Reich9, Ekin Şavk10, Esther Serra-Baldrich11, Markus Streit12, Jacek C Szepietowski13, Wolfgang Weger14, Martin Dugas3, Sonja Ständer2.   

Abstract

BACKGROUND: Chronic pruritus is a multifactorial, challenging symptom of global relevance.
OBJECTIVE: The European Academy of Dermatology and Venereology Network on Assessment of Severity and Burden of Pruritus (PruNet) investigation aimed to analyze the severity and humanistic burden of chronic pruritus in patients suffering from inflammatory dermatoses across Europe.
METHODS: Prospectively collected routine data on 552 patients (with atopic dermatitis, contact dermatitis, prurigo nodularis, psoriasis vulgaris, lichen planus, or mycosis fungoides [pruritus numeric rating scale score ≥3]) from 9 European centers (in Austria, France, Germany, Italy, Poland, Russia, Spain, Switzerland, and Turkey) were analyzed by univariate and multivariate variance analyses of various itch characteristics and quality of life (as measured by the Dermatology Life Quality Index and the ItchyQoL).
RESULTS: Duration, frequency, and intensity of pruritus (according to a numeric rating scale and visual analog scale) and related impairment of quality of life differed between European centers and dermatologic diagnoses (P < .05). The country in which the center was located had a greater impact on how patients evaluated pruritus intensity and quality of life than diagnosis did (P < .001). LIMITATIONS: One center per country was included.
CONCLUSION: The humanistic burden of chronic pruritus in patients with inflammatory dermatoses is high. European cross-cultural factors may have a stronger influence than a specific dermatologic diagnosis on how patients rate intensity of pruritus and quality of life.
Copyright © 2018 American Academy of Dermatology, Inc. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  care situation; humanistic burden; prurigo; pruritus intensity; pruritus measurement; quality of life

Mesh:

Year:  2018        PMID: 30119869     DOI: 10.1016/j.jaad.2018.04.044

Source DB:  PubMed          Journal:  J Am Acad Dermatol        ISSN: 0190-9622            Impact factor:   11.527


  13 in total

1.  A Nationwide Study of Prurigo Nodularis: Disease Burden and Healthcare Utilization in the United States.

Authors:  Shannon Wongvibulsin; Nishadh Sutaria; Kyle A Williams; Amy H Huang; Justin Choi; Youkyung Sophie Roh; Michael Hong; Davis Kelley; Vartan Pahalyants; William Murphy; Martin Prince Alphonse; Pegah Bakhshi; Anant Walia; Yevgeniy R Semenov; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-04-03       Impact factor: 7.590

2.  Prurigo Nodularis Is Characterized by Systemic and Cutaneous T Helper 22 Immune Polarization.

Authors:  Micah Belzberg; Martin Prince Alphonse; Isabelle Brown; Kyle A Williams; Raveena Khanna; Byron Ho; Shannon Wongvibulsin; Thomas Pritchard; Youkyung Sophie Roh; Nishadh Sutaria; Justin Choi; Jaroslaw Jedrych; Andrew D Johnston; Kakali Sarkar; Chirag Vasavda; Jimmy Meixiong; Carly Dillen; Kent Bondesgaard; John F Paolini; Wei Chen; David Corcoran; Nicolas Devos; Madan M Kwatra; Anna L Chien; Nathan K Archer; Luis A Garza; Xinzhong Dong; Sewon Kang; Shawn G Kwatra
Journal:  J Invest Dermatol       Date:  2021-03-23       Impact factor: 7.590

3.  Impact of Itch on Sleep Disturbance in Patients with Prurigo Nodularis.

Authors:  Eran C Gwillim; Leigh Nattkemper; Gil Yosipovitch
Journal:  Acta Derm Venereol       Date:  2021-03-31       Impact factor: 3.875

4.  Characteristics of Pruritus in Bullous Pemphigoid and Impact on Quality of Life: A Prospective Cohort Study.

Authors:  Clémence Briand; Greta Gourier; Florence Poizeau; Lamia Jelti; Marie Bachelerie; Gaëlle Quéreux; Géraldine Jeudy; Marie Acquitter; Saskia Ingen-Housz-Oro; Frédéric Caux; Catherine Prost; Anne-Sophie Darrigade; Diane Heron Mermin; Emmanuel Mahé; Catherine Picart Dahan; Marie-Aleth Richard; Caroline Jade Clerc; Camille Salle De Chou; Julie Plée; Claire Abasq-Thomas; Laurent Misery; Emilie Brenaut
Journal:  Acta Derm Venereol       Date:  2020-11-12       Impact factor: 3.875

5.  Investigator's Global Assessment of Chronic Prurigo: A New Instrument for Use in Clinical Trials.

Authors:  Claudia Zeidler; Manuel P Pereira; Matthias Augustin; Mary Spellman; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2021-02-17       Impact factor: 3.875

6.  Prevalence of Prurigo Nodularis in Poland.

Authors:  Anna Ryczek; Adam Reich
Journal:  Acta Derm Venereol       Date:  2020-05-28       Impact factor: 3.875

7.  Association between Prurigo Nodularis and Etiologies of Peripheral Neuropathy: Suggesting a Role for Neural Dysregulation in Pathogenesis.

Authors:  John-Douglas Matthew Hughes; Taylor E Woo; Micah Belzberg; Raveena Khanna; Kyle A Williams; Madan M Kwatra; Shahzeb Hassan; Shawn G Kwatra
Journal:  Medicines (Basel)       Date:  2020-01-08

8.  Chronic Prurigo: Similar Clinical Profile and Burden Across Clinical Phenotypes.

Authors:  Claudia Zeidler; Manuel Pedro Pereira; Sonja Ständer
Journal:  Front Med (Lausanne)       Date:  2021-06-29

Review 9.  Challenges in Clinical Research and Care in Pruritus.

Authors:  Manuel P Pereira; Claudia Zeidler; Michael Storck; Konstantin Agelopoulos; Wolfgang G Philipp-Dormston; Alexander Zink; Sonja Ständer
Journal:  Acta Derm Venereol       Date:  2020-01-07       Impact factor: 3.875

Review 10.  Quality of life in patients with Mycosis Fungoides and Sézary Syndrome: a systematic review of the literature.

Authors:  R Ottevanger; S van Beugen; A W M Evers; R Willemze; M H Vermeer; K D Quint
Journal:  J Eur Acad Dermatol Venereol       Date:  2021-08-14       Impact factor: 9.228

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.